HDAC Inhibition Induces Cell Cycle Arrest and Mesenchymal-Epithelial Transition in a Novel Pleural-Effusion Derived Uterine Carcinosarcoma Cell Line

Objective: Uterine carcinosarcoma (UCS) is a rare but highly aggressive malignancy with biphasic growth pattern. This morphology can be attributed to epithelial-mesenchymal transition (EMT) that often associates with tumor invasion and metastasis. Accordingly, we analyzed a novel patient-derived preclinical model to explore whether EMT is a potential target in UCS. Methods: A novel UCS cell line (PF338) was established from the malignant pleural effusion of a 59-year-old patient at time of disease progression. Immunohistochemistry was performed in primary and metastatic tumor lesions. Oncogenic mutations were identified by next-generation sequencing. Viability assays and cell cycle analyses were used to test in vitro sensitivity to different standard and novel treatments. E-cadherin, β-catenin and pSMAD2 expressions were measured by immunoblot. Results: Whereas immunohistochemistry of the metastatic tumor showed a predominantly sarcomatous vimentin positive tumor that has lost E-cadherin expression, PF338 cells demonstrated biphasic growth and carried mutations in KRAS, PIK3CA, PTEN and ARID1A. PF338 tumor cells were resistant to MEK- and TGF-β signaling-inhibition but sensitive to PIK3CA- and PARP-inhibition and first-line chemotherapeutics. Strikingly, histone deacetylase (HDAC) inhibition markedly reduced cell viability by inducing a dose-dependent G0/1 arrest and led to mesenchymal-epithelial transition as evidenced by morphological change and increased E-cadherin and β-catenin expression. Conclusions: Our data suggest that HDAC inhibition is effective in a novel UCS cell line by interfering with both viability and differentiation. These findings emphasize the dynamic manner of EMT/MET and epigenetics and the importance of molecular profiling to pave the way for novel therapies in UCS.

[1]  Da Yang,et al.  Targeting the TGFβ pathway in uterine carcinosarcoma , 2020, Cell stress.

[2]  D. Hayes,et al.  Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition , 2019, Proceedings of the National Academy of Sciences.

[3]  Hui Shen,et al.  ARID1A and PI3-kinase pathway mutations in the endometrium drive epithelial transdifferentiation and collective invasion , 2019, Nature Communications.

[4]  K. Okła,et al.  Histone Deacetylase Inhibitors and Phenotypical Transformation of Cancer Cells , 2019, Cancers.

[5]  T. Sugai,et al.  Immunohistochemical analysis of the epithelial to mesenchymal transition in uterine carcinosarcoma , 2019, International Journal of Gynecologic Cancer.

[6]  C. Gilks,et al.  High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations , 2018, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[7]  Benjamin G. Bitler,et al.  Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer , 2018, Cell reports.

[8]  A. Moreira,et al.  Carcinosarcomas and Related Cancers: Tumors Caught in the Act of Epithelial-Mesenchymal Transition. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Adam E. Hendry,et al.  The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth , 2017, Oncotarget.

[10]  Shaofeng Yan,et al.  Somatic mutation analysis in melanoma using targeted next generation sequencing. , 2017, Experimental and molecular pathology.

[11]  Kathleen R. Cho,et al.  ARID1A-mutated ovarian cancers depend on HDAC6 activity , 2017, Nature Cell Biology.

[12]  T. Sugai,et al.  Establishment and characterization of a novel uterine carcinosarcoma cell line, TU-ECS-1, with mutations of TP53 and KRAS , 2017, Human Cell.

[13]  Rehan Akbani,et al.  Integrated Molecular Characterization of Uterine Carcinosarcoma. , 2017, Cancer cell.

[14]  E. Seto,et al.  HDACs and HDAC Inhibitors in Cancer Development and Therapy. , 2016, Cold Spring Harbor perspectives in medicine.

[15]  F. Blackhall,et al.  Selumetinib in the treatment of non-small-cell lung cancer. , 2016, Future oncology.

[16]  B. Ghanim,et al.  Epigenetic down‐regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma , 2015, The Journal of pathology.

[17]  D. Huntsman,et al.  In‐depth molecular profiling of the biphasic components of uterine carcinosarcomas , 2015, The journal of pathology. Clinical research.

[18]  Resham Bhattacharya,et al.  Role of TGF-β signaling in uterine carcinosarcoma , 2015, Oncotarget.

[19]  M. Garcia-Blanco,et al.  Carcinosarcomas: tumors in transition? , 2015, Histology and histopathology.

[20]  Ethan Cerami,et al.  Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes , 2014, Nature Communications.

[21]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[22]  H. Saya,et al.  Expression profiles of carcinosarcoma of the uterine corpus—are these similar to carcinoma or sarcoma? , 2012, Genes, chromosomes & cancer.

[23]  C. Dai,et al.  Mechanism of the Mesenchymal–Epithelial Transition and Its Relationship with Metastatic Tumor Formation , 2011, Molecular Cancer Research.

[24]  Eric P Kaldjian,et al.  Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types. , 2010, Genes & cancer.

[25]  Kurt Zatloukal,et al.  Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo , 2010, Molecular Cancer.

[26]  Rochelle L. Garcia,et al.  Carcinosarcomas (malignant mixed Müllerian tumor) of the uterus: advances in elucidation of biologic and clinical characteristics. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[27]  Samy Lamouille,et al.  TGF-β-induced epithelial to mesenchymal transition , 2009, Cell Research.

[28]  T. Economopoulos,et al.  Combination chemotherapy with carboplatin, paclitaxel and pegylated liposomal doxorubicin for advanced or recurrent carcinosarcoma of the uterus: clinical experience of a single institution. , 2008, Gynecologic oncology.

[29]  A. Wells,et al.  E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas , 2008, Clinical & Experimental Metastasis.

[30]  A. Wolfson,et al.  A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. , 2007, Gynecologic oncology.

[31]  B. Gunawan,et al.  Characterization of a newly established uterine carcinosarcoma cell line featuring the sarcomatous phenotype of the tumor in vitro , 2007, International Journal of Gynecologic Cancer.

[32]  Gema Moreno-Bueno,et al.  Telling Cells How to Die: Docetaxel Therapy in Cancer Cell Lines , 2007, Cell cycle.

[33]  K. Zatloukal,et al.  Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells , 2006, Molecular Cancer Therapeutics.

[34]  T. Manabe,et al.  Expression of CD10 in Malignant Müllerian Mixed Tumors and Adenosarcomas: An Immunohistochemical Study , 2002, Modern Pathology.

[35]  L. Ramondetta,et al.  Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. , 2001, International journal of radiation oncology, biology, physics.

[36]  B. Monk,et al.  Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus , 2000, Cancer.

[37]  W. H. Kim,et al.  Establishment and characterization of cell lines derived from uterine malignant mixed Müllerian tumor. , 1997, Gynecologic oncology.

[38]  H. Minaguchi,et al.  Establishment and characterization of carcinosarcoma cell line of the human uterus , 1993, Cancer.

[39]  E. Oliva,et al.  Predictive Histologic Factors in Carcinosarcomas of the Uterus: A Multi-institutional Study. , 2019, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[40]  AACR Project GENIE: Powering Precision Medicine through an International Consortium. , 2017, Cancer discovery.

[41]  R. Bi,et al.  Clinicopathological characteristics , treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer ( G 3 EC ) patients : a comparative study , 2015 .

[42]  N. Wake,et al.  Expression and localization of E-cadherin and β-catenin in uterine carcinosarcoma , 2010, Virchows Archiv.

[43]  G. Moreno-Bueno,et al.  Docetaxel Therapy in Cancer Cell Lines , 2007 .

[44]  N. Tallada,et al.  An Immunohistochemical Study , 1992 .

[45]  Evon M. O. Abu-Taieh,et al.  Comparative Study , 2020, Definitions.

[46]  F. Askin,et al.  Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. , 1990, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.